Trials / Unknown
UnknownNCT05403333
Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II trial to explore the efficacy and safety of weekly utidelone in HER2-negative inoperable locally advanced or metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | utidelone | Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days |
Timeline
- Start date
- 2022-06-10
- Primary completion
- 2023-03-09
- Completion
- 2025-03-09
- First posted
- 2022-06-03
- Last updated
- 2022-06-03
Source: ClinicalTrials.gov record NCT05403333. Inclusion in this directory is not an endorsement.